T-LAK cell-originated protein kinase (TOPK): an emerging target for cancer-specific therapeutics by Herbert, K, Ashton, T, Prevo, R, Pirovano, G, Higgins, G

A role for human homologous recombination factors in suppressing microhomology-mediated end joining. by Ahrabi, S, Sarkar, S, Pfister, S, Pirovano, G, Higgins, G, Porter, A, Humphrey, T

[18F]FE-OTS964: A small molecule targeting TOPK for in vivo PET imaging in a glioblastoma xenograft model by Pirovano, G, Roberts, S, Brand, C, Donabedian, P, Mason, C, De Souza, P, Higgins, G, Reiner, T

CDK1 inhibition sensitizes normal cells to DNA damage in a cell cycle dependent manner by Prevo, R, Pirovano, G, Puliyadi, R, Herbert, K, Rodriguez-Berriguete, G, O'Docherty, A, Greaves, W, McKenna, W, Higgins, G

The anti-malarial drug atovaquone potentiates platinum-mediated cancer cell death by increasing oxidative stress by Coates, JTT, Rodriguez-Berriguete, G, Puliyadi, R, Ashton, T, Prevo, R, Wing, A, Granata, G, Pirovano, G, McKenna, GW, Higgins, GS

TOPK modulates tumour-specific radiosensitivity and correlates with recurrence after prostate radiotherapy by Pirovano, G, Ashton, T, Herbert, K, Bryant, R, Verrill, C, Cerundolo, L, Buffa, F, Prevo, R, Harrap, I, Ryan, A, Macaulay, V, McKenna, W, Higgins, G

The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia by Ashton, T, Fokas, E, Kunz-Schughart, L, Folkes, L, Anbalagan, S, Huether, M, Kelly, C, Pirovano, G, Buffa, F, Hammond, E, Stratford, M, Muschel, R, Higgins, G, McKenna, W

Increasing radiosensitivity by alleviating tumour hypoxia: a drug screen reveals atovaquone as a clinical candidate by Ashton, T, Fokas, E, Kunz-Schughart, L, Folkes, L, Anbalagan, S, Huether, M, Kelly, C, Pirovano, G, Buffa, F, Hammond, E, Stratford, M, Muschel, R, Higgins, G, McKenna, W